BioCurex, Inc. Receives Strong Upgrade by Respected Research Firm.

Management Introduces New Form of Cancer Detection with Results Superior to Most Widely Used Cancer Detection Test

RICHMOND, British Columbia -- BioCurex, Inc. (OTCBB: BOCX) is pleased to announce a well-respected firm, TRI-STATE Capital (TSC), has upgraded their equity rating on BOCX. This strong upgrade comes at a time when the company released early results indicating a new form of cancer detection exposing more than twice the amount of cancers than most widely used cancer detection test utilized today --- the PSA test.

TSC is noted for their work with, account executives, analysts, portfolio managers, institutions, venture capital investors, individual investors and the media. To view the entire independent research report, please click on the attached URL: http://www.otclive.com

Dr. Ricardo Moro, President and CEO of BioCurex states, "We are honored to have a quality independent research firm review our overall operations, progress and to provide the resulting upgrade in our stock. This offers further confirmation to our shareholders that our company is headed in the right direction". Mr. Moro further stated, "Our latest breakthrough brings us one step closer to commercialization of our unique cancer test."

To read more about the Company, please visit our web site (http://www.biocurex.com).

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.

BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAF(TM) Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the cancer marker RECAF(TM) has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.

Forward-Looking Statements:

This press release contains forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future. There are a number of factors that could cause actual results and developments to differ materially.